Log in or Sign up for Free to view tailored content for your specialty!
Oncology News
CStone initiates combination therapy trial for advanced liver cancer
CStone Pharmaceuticals received approval to initiate clinical development in China of a combination therapy for patients with locally advanced to metastatic hepatocellular carcinoma, according to a press release.
FDA approves treatment for liver cancer with high alpha-fetoprotein
Eli Lilly and Company announced that the FDA approved Cyramza for second-line treatment of patients with advanced hepatocellular carcinoma and high alpha-fetoprotein levels, according to a press release.
Log in or Sign up for Free to view tailored content for your specialty!
FDA approves Cyramza for hepatocellular carcinoma
The FDA approved ramucirumab as single-agent therapy for certain patients with hepatocellular carcinoma.
Can-Fite moves forward with advanced liver cancer therapy
The FDA granted both orphan drug designation and fast track status to Namodenoson, an advanced liver cancer therapy candidate from Can-Fite BioPharma, according to a press release.
Milciclib safe for advanced HCC in patients resistant to Nexavar
Tiziana Life Sciences announced that treatment with milciclib for advanced hepatocellular carcinoma did not correlate with unexpected signs or signals of toxicity based on results from an interim safety review, according to a press release.
Liver cancer mortality more common among those with lower education
Researchers found that the increased rates of liver cancer-related mortality in the United States were significantly linked to individuals with less education, especially among men.
Live donor liver offers improve transplant survival in patients with HCC
Patients with hepatocellular carcinoma who had a potential live donor at listing for liver transplantation had a significantly lower risk for mortality compared with those who waited for a deceased donor graft, according to recently published data.
Deaths related to intrahepatic bile duct cancer increasing globally
A recent analysis showed that mortality from intrahepatic cholangiocarcinoma has increased globally while mortality from extrahepatic cholangiocarcinoma has leveled off or decreased.
Advanced liver cancer therapy meets overall survival in cirrhosis subgroup
Can-Fite BioPharma announced that the phase 2 study of their advanced liver cancer candidate, Namodenoson, did not achieve its primary endpoint of overall survival, according to a press release.
Pipeline update: 8 recent advancements in liver disease therapy
Many chronic liver complications such as autoimmune hepatitis and nonalcoholic fatty liver disease do not have approved therapies for direct treatment, but the current hepatology pipeline includes several candidates that have recently demonstrated safety in early trials and some that met top-line phase 3 results.
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read